Purpose of Review

Chronic inflammation is a major contributor to cardiovascular disease (CVD) risk. Soluble urokinase plasminogen activator receptor (suPAR) is an immune-derived glycoprotein that is strongly associated with atherosclerotic disease. This review summarizes evidence on suPAR’s role in CVD pathogenesis and its potential as a prognostic indicator and therapeutic target.

Recent Findings

Clinical, genetic, and experimental evidence supports suPAR’s role as a pathogenic factor in atherosclerosis. suPAR promotes atherosclerosis through modulation of monocyte activation and function. Clinically, elevated suPAR levels are linked to increased cardiovascular risk across diverse populations. Ongoing clinical trials are evaluating therapies targeting suPAR signaling.

Summary

Current evidence positions suPAR as a regulator of myeloid cell function that contributes to vascular inflammation and subsequent cardiovascular events. Additional research is needed to determine whether suPAR measurement can improve CVD risk prediction and enable personalized management. Overall, suPAR is a promising immune-derived biomarker and target for reducing inflammation and cardiovascular risk.

中文翻译：

---

可溶性尿激酶型纤溶酶原激活剂受体在心血管疾病中的作用

审查目的

慢性炎症是心血管疾病 (CVD) 风险的主要原因。可溶性尿激酶纤溶酶原激活剂受体 (suPAR) 是一种免疫源性糖蛋白，与动脉粥样硬化疾病密切相关。本综述总结了 suPAR 在 CVD 发病机制中的作用及其作为预后指标和治疗靶点的潜力的证据。

最近的发现

临床、遗传和实验证据支持 suPAR 作为动脉粥样硬化致病因素的作用。suPAR 通过调节单核细胞活化和功能促进动脉粥样硬化。临床上，suPAR 水平升高与不同人群的心血管风险增加有关。正在进行的临床试验正在评估针对 suPAR 信号传导的疗法。

概括

目前的证据表明 suPAR 是骨髓细胞功能的调节剂，可导致血管炎症和随后的心血管事件。需要进行更多研究来确定 suPAR 测量是否可以改善 CVD 风险预测并实现个性化管理。总体而言，suPAR 是一种有前途的免疫衍生生物标志物和减少炎症和心血管风险的靶标。